Dronabinol/acetazolamide
| Combination of | |
|---|---|
| Dronabinol | Cannabinoid |
| Acetazolamide | Carbonic anhydrase inhibitor |
| Clinical data | |
| Other names | IHL-42X |
| Legal status | |
| Legal status |
|
Dronabinol/acetazolamide (investigational name IHL-42X) is a combination therapy under investigation for sleep apnea. It is developed by Incannex Healthcare.[1][2]
References
[edit]- ^ Walsh, J; Rankin, T; Mehra, S; Naughton, M; Roebuck, T; McDermott, E; Pattichis, A; Smith, R; Germaine, J; Walsh, R; Bleackley, M; Maddison, K; O'Brien, T (9 November 2022). "O027 A randomised dose finding study of combination dronabinol and acetazolamide for the treatment of obstructive sleep apnoea: A proof of concept study". Sleep Advances: A Journal of the Sleep Research Society. 3 (Suppl 1): A11. doi:10.1093/sleepadvances/zpac029.026. ISSN 2632-5012. PMC 10109426.
- ^ Thomson, Luke; Rankin, Timothy; Mehra, Sumit; Naughton, Matthew; Roebuck, Teanau; McDermott, Elizabeth; Pattichis, Andreas; Smith, Rafael; Germaine, Jack; Walsh, Rosemarie; Bleackley, Mark; Edwards, Bradley; Maddison, Kathleen; O'Brien, Terence; Walsh, Jen (29 May 2023). "0451 Dronabinol Plus Acetazolamide for the Treatment of Obstructive Sleep Apnoea: A Proof of Concept and Mechanistic Exploration Study". SLEEP. 46 (Supplement_1): A200–A201. doi:10.1093/sleep/zsad077.0451.